Sugi Predict

Sugi Predict / Compounds / SCHEMBL348272

SCHEMBL348272

SCHEMBL348272

Cc1cc(N)c([N+](=O)[O-])cc1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.59
▸ ALDH1A1 P00352 5/20 0.53
▸ CYP3A4 P08684 4/20 0.53
▸ RECQL P46063 1/20 0.53
▸ TDP1 Q9NUW8 6/20 0.52
▸ MAPT P10636 6/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ POLB P06746 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ MCL1 Q07820 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ HSP90AA1 P07900 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ CCR6 P51684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11219818 0.91 TSHR (0.59) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL30578459 0.91 TSHR (0.59) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL7461987 0.89 TSHR (0.57) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL10488867 0.89 TSHR (0.57) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL9652342 0.89 TSHR (0.57) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL30675090 0.84 TSHR (0.57) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL6672279 0.84 TSHR (0.57) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL772636 0.84 CD44 (0.54) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL5949104 0.84 TSHR (0.52) TSHRALDH1A1CYP3A4RECQLTDP1
SCHEMBL2374034 0.84 TSHR (0.52) TSHRALDH1A1CYP3A4RECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119707773-A Preparation method and application of maleimide structure-containing compound 中国农业大学 2025-03-28 — — CN claimed
CN-119080702-A Synthesis method of environment-friendly 5, 6-dimethyl benzoimidazole 河北科硕化工有限公司 2024-12-06 — — CN claimed
CN-114591180-B Preparation method of 4,4', 5' -tetramethyl [1,1 '-biphenyl ] -2,2' -diamine 绍兴贝斯美化工股份有限公司 2024-09-06 — — CN claimed
CN-114591180-A Preparation method of 4,4',5,5' -tetramethyl [1,1 '-biphenyl ] -2,2' -diamine 绍兴贝斯美化工股份有限公司 2022-06-07 — — CN claimed
CN-108276366-B Acrylamide derivative and preparation method and application thereof 四川大学 2021-09-03 — — CN claimed
CN-108084448-B Cadmium polymerization complex containing 4, 5-dimethyl-1, 2-phenylenediamine derivative and preparation method and application thereof 湘潭大学 2020-10-30 — — CN claimed
CN-108084448-A One kind -1,2- of dimethyl containing 4,5- phenylenediamine derivatives close cadmium oligometric comples and preparation method and purposes 湘潭大学 2018-05-29 — — CN claimed
EP-0377112-B1 Quinoxaline compounds and their preparation and use NOVO NORDISK AS (DK) 1994-08-24 — — EP claimed
JP-7179409-A — — None — — JP disclosed
EP-3746436-B1 FUSED RING COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-05-20 — — EP disclosed
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2026-01-20 — — US disclosed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
CN-117843616-B 3-Cyano-substituted quinoline compound, and pharmaceutical composition and application thereof 中国药科大学 2025-05-27 — — CN disclosed
EP-4540255-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
EP-0059884-A1 Benzofurane derivatives, their preparation and use SCHERING AKTIENGESELLSCHAFT (DE) 1982-09-15 — — EP disclosed
EP-0056475-A2 Pharmaceutical compositions MERCK PATENT GmbH (DE) 1982-07-28 — — EP disclosed
US-4216320-A Quinoxaline bleach catalysts CIBA-GEIGY AG (CH) 1980-08-05 — — US disclosed
US-4185018-A Process for producing benzofurazan-1-oxides CIBA-GEIGY CORPORATION (US) 1980-01-22 — — US disclosed
US-4145217-A DYE BLEACH CATALYST CIBA-GEIGY AG (CH) 1979-03-20 — — US disclosed
US-3931215-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS TSHR 1916/4885ALDH1A1 3667/4885CYP3A4 2631/4885
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors F2RL3, F2R, PF4 TSHR 640/4885ALDH1A1 1173/4885CYP3A4 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.